Evidence map›Paper›PMID 26416860›Full record

ArticleAntimicrobial agents and chemotherapy2015

In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program.

Douglas J Biedenbach, Daryl J Hoban, Edina Reiszner, Sushmita D Lahiri, Richard A Alm, Daniel F Sahm, Samuel K Bouchillon, Jane E Ambler

Abstract readMulticenter Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Antimicrobial resistance in methicillin-resistantAntimicrobial agents and chemotherapy · 2019
    Review
  4. Review
  5. Acta pharmaceutica Sinica. B · 2019
    Article
  6. PBP4: A New Perspective onMicroorganisms · 2018
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Douglas J BiedenbachInternational Health Management Associates, Inc., Schaumburg, Illinois, USA.
Daryl J HobanInternational Health Management Associates, Inc., Schaumburg, Illinois, USA.
Edina ReisznerAstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA.
Sushmita D LahiriAstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA.
Richard A AlmAstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA.
Daniel F SahmInternational Health Management Associates, Inc., Schaumburg, Illinois, USA dsahm@ihmainc.com.
Samuel K BouchillonInternational Health Management Associates, Inc., Schaumburg, Illinois, USA.
Jane E AmblerAstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The in vitro activities of ceftaroline and comparators, using broth microdilution, were determined against 1,066 Staphylococcus aureus isolates from hospitalized patients. Seventeen medical centers from Latin American countries contributed isolates. Methicillin-resistant S. aureus (MRSA) percentages ranged from 46% (Brazil) to 62% (Argentina). All methicillin-susceptible S. aureus (MSSA) isolates were susceptible to ceftaroline. Ceftaroline activity against MRSA varied with MIC90s of 0.5 (Venezuela) to 2 (Brazil, Chile, and Colombia) μg/ml, which was the highest MIC value. ST-5 was the most common sequence type.

Indexed as

Public Health SurveillanceAnti-Bacterial AgentsCeftarolineCephalosporinsHospitalizationHumansLatin AmericaMethicillin ResistanceMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsStaphylococcal InfectionsAnti-Bacterial AgentsCeftarolineCephalosporins

Identifiers

PMID26416860
PMCPMC4649166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.